ZOLPIMIST Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zolpimist, and when can generic versions of Zolpimist launch?
Zolpimist is a drug marketed by Aytu and is included in one NDA. There is one patent protecting this drug.
This drug has eighty-six patent family members in nine countries.
The generic ingredient in ZOLPIMIST is zolpidem tartrate. There are thirty-three drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zolpimist
A generic version of ZOLPIMIST was approved as zolpidem tartrate by ACME LABS on April 23rd, 2007.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZOLPIMIST?
- What are the global sales for ZOLPIMIST?
- What is Average Wholesale Price for ZOLPIMIST?
Summary for ZOLPIMIST
| International Patents: | 86 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for ZOLPIMIST |
| What excipients (inactive ingredients) are in ZOLPIMIST? | ZOLPIMIST excipients list |
| DailyMed Link: | ZOLPIMIST at DailyMed |
US Patents and Regulatory Information for ZOLPIMIST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aytu | ZOLPIMIST | zolpidem tartrate | SPRAY, METERED;ORAL | 022196-001 | Dec 19, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZOLPIMIST
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Aytu | ZOLPIMIST | zolpidem tartrate | SPRAY, METERED;ORAL | 022196-001 | Dec 19, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Premature patent expiration for: ZOLPIMIST
International Patents for ZOLPIMIST
See the table below for patents covering ZOLPIMIST around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 4894697 | Buccal, polar and non-polar spray or capsule | ⤷ Sign Up |
| New Zealand | 561128 | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract | ⤷ Sign Up |
| European Patent Office | 1675568 | PULVERISATEUR ORAL, POLAIRE ET NON POLAIRE, CONTENANT DU ZOLPIDEM (BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ZOLPIDEM) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2004043428 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZOLPIMIST
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2236132 | CA 2015 00004 | Denmark | ⤷ Sign Up | PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718 |
| 2236132 | 92636 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES |
| 2236132 | 122015000006 | Germany | ⤷ Sign Up | PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718 |
| 2236132 | C300714 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
